October 23, 2006 09:52 ET

Hot Stocks to Watch for Monday, October 23, 2006: Exclusive Worldwide Production, Sales, and Marketing Rights!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL--(Marketwire - October 23, 2006) - announces the following stocks to its Hot Stocks List: Xechem International Inc. (OTCBB: XKEM), VIVUS, Inc. (NASDAQ: VVUS), Replidyne, Inc. (NASDAQ: RDYN), Lumera Corp (NASDAQ: LMRA)

Xechem International, Inc. (OTCBB: XKEM) just announced the United States Patent and Trademark Office has issued to Virginia Commonwealth University (VCU) a notice of patent allowance relating to a method of treating Sickle Cell Disease (SCD) with a unique 5-membered heterocyclic anti-sickling agent known as 5-HMF. A notice of allowance is a written notification that a patent application has cleared an internal review and is nearing issuance.

The exclusive, worldwide rights for the production, sales and marketing of 5-HMF for use in the battle against SCD belong to Xechem as part of a collaborative licensing agreement with VCU. In May 2006, Xechem was successful in obtaining Orphan Drug designation from the US Food and Drug Administration (FDA) for use of 5-HMF by patients afflicted with SCD. Xechem also announced recently that it has received a SBIR grant in the amount of $473,181 from the National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NHLBI) to carry out the toxicity studies on 5-HMF.

Other stocks highlighted include VIVUS, Inc. (NASDAQ: VVUS): Hot Stocks List, up 1% on 1 million shares, Replidyne, Inc. (NASDAQ: RDYN): Hot Stocks List, down 1% on 1 million shares, Lumera Corp (NASDAQ: LMRA): Hot Stocks List, down 1% on 3 million shares.

"Federal Reserve policymakers left interest rates unchanged after their most recent meeting on September 20, for a second straight time, signaling that the central back doesn't believe inflation is at the moment and that growth in the economy has slowed to a moderate pace. A sharp drop in oil prices has helped stem inflation fears, although the core rate is more closely watched by the Federal Open Market Committee." More is available at:'s Daily Stock Updates:, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated thirty thousand dollars for XKEM. CRG was compensated one hundred twenty thousand dollars in past compensation for XKEM. CRG intends to sell its shares. CRG has sold approximately zero XKEM shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information

  • Chuck Tamburello
    Phone: 954-217-8555
    Fax: 954-217-1500